Blog
RSS FeedPosted by Michael Wonder on 09 Sep 2022
Rare cancer sufferers fight to get drugs on PBS
9 September 2022 - People with rare cancers are being forced to sell their homes, raid their superannuation and fundraise ...
Posted by Michael Wonder on 05 Sep 2022
Review of Efficient Funding of Chemotherapy Program - interim report
5 September 2022 - The Efficient Funding of Chemotherapy review seeks to investigate current processes involved in the production, distribution ...
Posted by Michael Wonder on 01 Sep 2022
Antengene announces Xpovia included for reimbursement by the PBS in Australia for the treatment of patients with relapsed and/or refractory multiple myeloma
1 September 2022 - Xpovio (selinexor) is the first and only selective inhibitor of nuclear export (SINE) inhibitor approved by the ...
Posted by Michael Wonder on 01 Sep 2022
PBS listing for ovarian cancer and kidney disease
1 September 2022 - From 1 September 2022, Australians will have access to new and expanded medicines on the Pharmaceutical Benefits ...
Posted by Michael Wonder on 28 Aug 2022
Ovarian cancer drug that costs up to $130k will soon be affordable for hundreds of patients
28 August 2022 - A drug that works to prolong survival for some patients with advanced ovarian cancer is being ...
Posted by Michael Wonder on 19 Aug 2022
1 September 2022 updates as part of the digital transformation of authority required (written) PBS listings
19 August 2022 - From 1 September 2022, the PBS listings for certain cancer medicines will be updated as part of ...
Posted by Michael Wonder on 03 Jul 2022
Rare blood cancer drug Brukinsa to be listed for the first time on Pharmaceutical Benefits Scheme
1 July 2022 - Graeme Anderson had just finished seven days of night shift when he first noticed something didn’t feel ...
Posted by Michael Wonder on 30 Jun 2022
PBS listing for ‘Australian success story’ blood cancer drug
1 July 2022 - A pill that removes the need for chemotherapy for some cancer sufferers has been put on ...
Posted by Michael Wonder on 19 Jun 2022
Current issues in health technology assessment of cancer therapies: a survey of stakeholders and opinion leaders in Australia
17 June 2022 - The aim of this study was to find ways of bridging the gap in opinions concerning health ...
Posted by Michael Wonder on 01 May 2022
Cost of some life-saving drugs to be slashed
1 May 2022 - Changes to the PBS could save some Australians as much as $2.5 million per treatment, as others ...
Posted by Michael Wonder on 27 Apr 2022
Insights from the March 2022 PBAC meeting (part 2)
28 April 2022 The rejection of dostarlimab should not come as a surprise, the rejection of sotorsaib less so. ...
Posted by Michael Wonder on 26 Apr 2022
PBS brings hope to cancer patients
25 April 2022 - Late-stage breast cancer patients, many of them young women, will have access to a life-extending medication ...
Posted by Michael Wonder on 01 Apr 2022
Price slashed for revolutionary $78,000 a year prostate cancer treatment Lynparza
1 April 2022 - A new subsidy for a revolutionary drug is set to benefit thousands of Aussie men with aggressive ...
Posted by Michael Wonder on 29 Mar 2022
Federal budget 2022: more funding for breast cancer drug Trodelvy
29 March 2022 - Against all the odds Sydney mum Alison Day will get to celebrate her daughter’s 12th birthday — ...
Posted by Michael Wonder on 21 Mar 2022
Mum’s fear as promising cancer drug out of reach
21 March 2022 - A terminally ill mum desperate for “more time” with her family was “broken” when she learnt the ...